Christopher Sweeney Named Executive Director, Intellectual Property
Acuitas Therapeutics, Inc.’s Chief Legal Officer & Vice President of Business Development, Miranda Lam, KC, recently announced that Christopher Sweeney has joined Acuitas Therapeutics (USA), Inc. as Executive Director of Intellectual Property (IP). In this senior role, Mr. Sweeney oversees the
Dr. Ghania Chikh: Expertise, Experience and Engagement with the Team!
The Acuitas team consists of brilliant, talented and experienced scientists and business professionals who are also interesting, engaging and fun-loving. This is just one of the many things that makes us unique at Acuitas. For Acuitas, the word “team” isn’t based
Welcome, Kyle Stephenson
Acuitas continues to grow (in size and geographic region), and we are thrilled to announce that Dr. Kyle Stephenson has joined the team as Director, Preclinical. While Kyle is based in the Greater Toronto Area (GTA), he will regularly be
Acuitas Is a Great Place to Work! (Why You Should Work Here!)
Finding a great place to work which is purpose driven is a goal for many, and we completely understand (and endorse!) that. Good work/life integration is an important aspect of our professional lives – and so is working with a
Our Unique Business Model
The Acuitas business model is unique. As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, our full focus is on refining and improving our LNP for use by our partners. Supporting partner success is at the heart
Acuitas – Who We Are and How We Got Here
As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, the Acuitas team advances human health through our work with our partners – and by continuing to refine and improve our LNP. We are growing our team and
Acuitas Scientists Co-Author Nature Article
Acuitas Therapeutics’ Chief Scientific Officer, Dr. Ying Tam, and Director of Formulation Development, Paulo Lin, co-authored (with several other scientists) a study titled “Molecular fate-mapping of serum antibody responses to repeat immunization” that was recently published in Nature. Please click
Acuitas Therapeutics Video Update
Acuitas Therapeutics is the global leader in the field of lipid nanotechnology. We specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). We work with partners to develop new therapies to address unmet
Why I Work at Acuitas – Science & Social Fun
The third blog post in our series: “Why I Work at Acuitas” features Research Scientist, Reihaneh Hosseinzadeh. We recently caught up with Ms. Hosseinzadeh and she told us why she chose to work at Acuitas Therapeutics. From as far back as
Why I Work at Acuitas – A Project Manager’s Perspective
Today’s installment in our "Why I Work at Acuitas" series is with Acuitas’ Sr. Associate, Project Manager, Dr. Baishakhi Datta. We recently caught up with Dr. Datta and asked her a few questions about why she chose to work at